If You Invested in Theravance Bioph (TBPH)

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a biopharmaceutical company in the pharmaceutical preparation manufacturing industry that focuses on discovering, developing and commercializing organ-selective medicines. According to company disclosures, its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs, with research centered on inflammation, immunology, and serious respiratory and neurologic conditions.

The company states that it applies organ-selective expertise to target disease biologically, aiming to expand the therapeutic index of its medicines by maximizing efficacy while limiting systemic side effects. This focus has led to the development of YUPELRI (revefenacin) inhalation solution, an FDA-approved lung-selective medicine indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is described as the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) bronchodilator approved in the U.S. for COPD maintenance treatment, and Viatris records total net sales while Theravance Biopharma receives collaboration revenue based on a share of those sales.

Theravance Biopharma also highlights a late-stage investigational program in neurology. Its key pipeline asset, ampreloxetine, is an investigational, once-daily, selective norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a rare, progressive neurodegenerative disorder. The company reports that ampreloxetine has been granted Orphan Drug Designation in the U.S. for the treatment of symptomatic nOH in patients with MSA.

Core products and programs

YUPELRI (revefenacin) inhalation solution is a central commercial product for Theravance Biopharma. It is indicated for the maintenance treatment of patients with COPD and is delivered via nebulization once daily. Company communications describe YUPELRI as a lung-selective medicine and emphasize its role as a maintenance therapy for COPD patients. Theravance Biopharma records collaboration revenue from its partner Viatris, which books total net sales and shares a portion of those sales and commercial costs with Theravance Biopharma.

Ampreloxetine is described as a late-stage, investigational, once-daily selective norepinephrine reuptake inhibitor being developed for symptomatic nOH in patients with MSA. The company reports that in a prior study in MSA patients (Study 0170, REDWOOD), ampreloxetine treatment was associated with increased norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertension in the MSA subgroup. Based on these findings, Theravance Biopharma has designed and is conducting the Phase 3 CYPRESS (Study 0197) trial as a registrational, multi-center, randomized withdrawal study in patients with MSA and symptomatic nOH.

Clinical development focus

The CYPRESS (Study 0197) Phase 3 trial is described as a registrational, multi-center, randomized withdrawal study evaluating the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. The study includes four periods: a screening phase, a 12-week open-label period where participants receive a single daily 10 mg dose of ampreloxetine, an eight-week double-blind, placebo-controlled randomized withdrawal period (with participants receiving either placebo or ampreloxetine once daily), and a long-term treatment extension. The primary endpoint is change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score, with secondary endpoints including changes in items of the Orthostatic Hypotension Daily Activity Scale (OHDAS) related to standing and walking.

Earlier Phase 3 studies, SEQUOIA (Study 0169) and REDWOOD (Study 0170), evaluated ampreloxetine in a broader symptomatic nOH population that included patients with Parkinson’s disease, pure autonomic failure, and MSA. While the overall program did not meet its primary endpoint in the full population, Theravance Biopharma reports that a pre-specified subgroup analysis suggested that benefits were largely driven by MSA patients, with improvements across multiple symptom and activity scales in that subgroup. These observations informed the company’s decision to focus the CYPRESS registrational study on MSA-related nOH.

Disease areas of interest

Theravance Biopharma’s disclosed areas of focus include:

• Chronic obstructive pulmonary disease (COPD), through the commercial product YUPELRI (revefenacin) inhalation solution for maintenance treatment.
• Multiple system atrophy (MSA), a progressive brain disorder affecting movement, balance, and autonomic function, with a high prevalence of symptomatic nOH.
• Neurogenic orthostatic hypotension (nOH), a rare disorder characterized by a significant drop in blood pressure upon standing, leading to symptoms such as dizziness, lightheadedness, fainting, fatigue, blurry vision, weakness, trouble concentrating, and head and neck pain.
• Broader inflammation and immunology research, as indicated in the company’s stated research focus.

Geographic and regulatory context

Theravance Biopharma, Inc. is incorporated in the Cayman Islands and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-36033. Its principal executive offices are associated with Theravance Biopharma US, LLC in South San Francisco, California, as reflected in multiple Form 8-K filings. The company’s common stock trades on the NASDAQ under the ticker symbol TBPH.

The company reports that its partner Viatris has secured regulatory approval from China’s National Medical Products Administration (NMPA) for YUPELRI (revefenacin) inhalation solution as the first once-daily nebulized LAMA approved for maintenance treatment of COPD in China. Under this arrangement, Viatris is responsible for development and commercialization of YUPELRI in China, while Theravance Biopharma is eligible for milestones and tiered royalties on net sales in that market.

Business model elements

Based on Theravance Biopharma’s public statements, its business model combines:

• Commercial participation in partnered products, notably YUPELRI, where Viatris records total net sales and Theravance Biopharma recognizes collaboration revenue representing its share of net sales and commercial costs.
• Late-stage clinical development of proprietary assets such as ampreloxetine, with a focus on rare, severe conditions like MSA-related nOH.
• Intellectual property and litigation management, including patent portfolios related to YUPELRI and settlement agreements with generic manufacturers as disclosed in SEC filings.

The company has also disclosed the formation of a Strategic Review Committee of independent directors to assess strategic alternatives and has emphasized disciplined capital allocation and returning excess cash to shareholders, as described in its corporate updates.

Educational and scientific engagement

Theravance Biopharma reports active engagement with the medical and scientific community. It has launched a disease education campaign for healthcare professionals, "Power in the Periphery," to raise awareness and deepen scientific understanding of the pathophysiology underlying nOH associated with MSA. The company also participates in scientific meetings, including the International Symposium on the Autonomic Nervous System and the CHEST Annual Meeting, where it presents data on YUPELRI and ampreloxetine.

In addition, Theravance Biopharma organizes and participates in investor-focused events, such as key opinion leader (KOL) sessions that review clinical development programs and discuss unmet medical needs in MSA-related nOH. These activities reflect the company’s stated focus on specialty respiratory and neurologic diseases and its goal of delivering "Medicines that Make a Difference" in patients’ and caregivers’ lives.

Theravance Biopharma stock (TBPH)

Theravance Biopharma’s shares trade on NASDAQ under the symbol TBPH. Investors and analysts follow TBPH stock in connection with the performance of YUPELRI, progress of the ampreloxetine clinical program, milestones related to partnered assets such as TRELEGY, and updates from the company’s strategic and financial reviews. The company files periodic and current reports with the SEC, including Form 8-K filings that provide updates on clinical milestones, financial results, patent settlements, and regulatory events.

Key focus areas summarized

• Discovery, development, and commercialization of organ-selective small-molecule medicines.
• Commercial participation in YUPELRI (revefenacin) inhalation solution for COPD maintenance treatment.
• Late-stage development of ampreloxetine for symptomatic nOH in patients with MSA, including the registrational Phase 3 CYPRESS study.
• Research focus in inflammation, immunology, respiratory disease, and neurologic conditions involving autonomic dysfunction.
• Engagement in disease education and scientific dissemination around MSA and nOH.